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Objective: Acute kidney injury requiring continuous renal replace-
ment therapy is a serious treatment-related complication in pediatric 
cancer and hematopoietic stem cell transplant patients. The purpose 
of this study was to assess epidemiology and outcome of these 
patients requiring continuous renal replacement therapy in the PICU.
Design: A nationwide, multicenter, retrospective, observational 
study.
Setting: Eight PICUs of a tertiary care hospitals in the Nether-
lands.
Patients: Pediatric cancer and hematopoietic stem cell transplant 
patients (cancer and noncancer) who received continuous renal re-
placement therapy from January 2006 to July 2017 in the Netherlands.
Interventions: None.
Measurement and Main Results: Of 1,927 PICU admissions of 
pediatric cancer and hematopoietic stem cell transplant patients, 
68 of 70 evaluable patients who received continuous renal re-
placement therapy were included. Raw PICU mortality was 11.2% 
(216/1,972 admissions). PICU mortality of patients requiring con-
tinuous renal replacement therapy was 54.4% (37/68 patients). 
Fluid overload (odds ratio, 1.08; 95% CI, 1.01–1.17) and need for 
inotropic support (odds ratio, 6.53; 95% CI, 1.86–23.08) at the 
start of continuous renal replacement therapy were associated with 
PICU mortality. Serum creatinine levels increased above 150% of 
baseline 3 days before the start of continuous renal replacement 
therapy. Urine production did not reach the critical limit of oliguria. 
In contrast, body weight (fluid overload) increased already 5 days 
prior to continuous renal replacement therapy initiation.
Conclusions: PICU mortality of pediatric cancer and hematopoi-
etic stem cell transplant patients requiring continuous renal re-
placement therapy is sadly high. Fluid overload at the initiation of 
continuous renal replacement therapy is the most important and 
earliest predictor of PICU mortality. Our results suggest that the 
most commonly used criteria of acute kidney injury, that is, serum 
creatinine and urine production, are not useful as a trigger to ini-
tiate continuous renal replacement therapy. This highlights the ur-
gent need for prospective studies to generate recommendations 
for effective therapeutic interventions at an early phase in this spe-
cific patient population. (Crit Care Med 2019; 47:e893–e901)DOI: 10.1097/CCM.0000000000003973
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Over the last decades, outcome of pediatric cancer and hematopoietic stem cell transplant (HSCT) patients has substantially improved by the introduction of 
more targeted treatment protocols and advanced supportive 
therapy. As a consequence, outcomes for these children have 
evolved from an estimated 20% survival in the late 80s to an 
80% survival at this time (1–3). However, these developments 
also have increased morbidity, that is, disease- or treatment-
associated complications, many of which require intensive care 
treatment (4–7).
Acute kidney injury (AKI) is one of these serious com-
plications, being multifactorial in etiology. The need for 
nephrotoxic medication, including chemotherapeutics, anti-
biotics, and immunosuppressants, contributes to renal injury. 
Furthermore, intervention in these patients during critical ill-
ness frequently requires a high volume of IV fluids administra-
tion, including the need for blood products, which seriously 
increases the risk of fluid overload (8–10).
Continuous renal replacement therapy (CRRT) has become 
the most widely used modality of renal replacement in critically 
ill children with renal dysfunction, fluid overload, and/or elec-
trolyte imbalances as it allows continuous and programmed 
removal of fluids as well as nitrous waste products (11–14). 
However, its use in the complex setting of critically ill pediatric 
cancer and HSCT patients with various components of mul-
tiple organ dysfunction is challenging and sometimes contro-
versial. Studies on outcome of critically ill patients requiring 
CRRT have been mostly pursued in the general PICU popula-
tion, and none of these studies assessed outcomes specifically 
in pediatric cancer and HSCT patients. A better understanding 
of the impact of the need for CRRT on both short- and long-
term outcomes among these children and factors that influ-
ence these outcomes is essential for optimal implementation of 
this therapy in pediatric oncology intensive care settings.
The purpose of the current national study was to assess 
the epidemiology and outcome of pediatric cancer and HSCT 
patients who required CRRT in the PICU. In addition, we 
sought to identify risk factors for mortality in the PICU set-
ting and we have examined the behavior of the determinants 




This retrospective study included all pediatric cancer and HSCT 
(oncologic and nononcologic) patients who received CRRT in 
one of the eight Dutch PICUs from January 2006 to July 2017. 
The exclusion criteria were a preexisting estimated glomerular 
filtration rate (eGFR) below 15 mL/min/1.73 m2 of body surface 
area, maintenance dialysis, or receipt of kidney transplant in the 
preceding 90 days before the start of CRRT (15).
The study was approved by the institutional ethical review 
boards of the participating hospitals (reference number: 17–
028/C). Need for informed consent was waived.
Complete details of the study design are provided in the 
online supplement (Supplemental Digital Content 1, http://
links.lww.com/CCM/E888).
Data Collection
Data were collected for each CRRT episode. Baseline patient 
characteristics and variables regarding PICU admission and 
treatment were obtained from medical records. Disease se-
verity at PICU admission was assessed using the Pediatric 
Index of Mortality (PIM) 2 score (16).
Renal function data assessed included SCr levels, urine output, 
eGFR, AKI stage, and the percentage fluid overload 7 consecu-
tive days before and at the start of CRRT. AKI was defined and 
classified according to the Kidney Disease: Improving Global 
Outcomes (KDIGO) criteria, which include incremental changes 
of SCr and decremental urine output (17). In addition, follow-up 
data on renal function 3 months after PICU discharge, including 
eGFR and chronic kidney disease (CKD) stage, were collected. 
SCr was adjusted for fluid balance according to the following for-
mula: corrected creatinine = measured creatinine × (1 + [accu-
mulated net fluid balance/total body water]), where total body 
water = 0.6 × weight (kg) (18–20). Details on data collection and 
definitions are described in the online supplement (Supplemental 
Digital Content 1, http://links.lww.com/CCM/E888).
Outcomes
The primary outcome was PICU mortality. Secondary out-
comes were 3-month mortality, renal function status at 3 
months after PICU discharge (resolution, new-onset CKD, or 
worsening of preexisting CKD) (17), resource utilization by 
measurement of PICU length of stay, and the days of use of 
PICU technologies such as mechanical ventilation and ino-
tropic/vasopressor support.
Statistical Analysis
Categorical variables were displayed as frequencies (%) and 
compared using chi-square or Fisher exact test. Normality 
was tested with the Kolmogorov-Smirnov test. Continuous 
variables were displayed as medians with interquartile ranges 
(IQRs) or as means ± sds, based on data distribution, and were 
compared with the Wilcoxon rank-sum test. With respect to 
missing data, multiple imputation was used (Supplementary 
Table S1, Supplemental Digital Content 1, http://links.lww.
com/CCM/E888). From seven of the 68 patients, data of SCr, 
urine production, and fluid overload in the 7 consecutive days 
before initiation of CRRT were missing. These patients were 
excluded in the analysis of the course of these parameters.
Variables were evaluated for an association with PICU mor-
tality using multivariate logistic regression analysis after con-
trolling for potential confounders. Odds ratio (OR) and their 
corresponding 95% CIs were calculated. Variables were entered 
into the model when the α level of the risk factor was less than 
0.15 in univariate analysis.
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The continuous variable “degree of fluid overload” was di-
vided into severity strata for univariate analyses: 0% to less 
than or equal to 3%, 3% to less than or equal to 10%, greater 
than 10% to less than or equal to 20%, greater than 20%. In 
addition, percentage of fluid overload was also analyzed as a 
continuous variable.
P values of less than 0.05 were considered to be signifi-




During the study period, there were 59,864 PICU admissions in 
the Netherlands, of which 1,927 admissions had an underlying 
malignancy or had undergone HSCT. Seventy of these 1,927 
patients received CRRT (3.6%). Data on two patients were not 
available, leaving 68 patients, for inclusion in the analyses (Fig. 1).
Patient demographic and clinical characteristics are shown 
in Table 1. The median age was 8.9 years (IQR, 3.3–8.9 yr). 
The majority of patients had leukemia/lymphoma (n = 38; 
55.9%) or a solid tumor (n = 17; 25.0%) as underlying cancer 
diagnosis. One third of the patients had undergone HSCT 
(n = 23; 11 patients with cancer as part of their treatment and 
12 noncancer). A detailed description of the HSCT patients is 
presented in Supplementary Table S2 (Supplemental Digital 
Content 1, http://links.lww.com/CCM/E888). All patients re-
ceived continuous venovenous hemofiltration, continuous 
venovenous hemodialysis, or continuous venovenous hemo-
diafiltration. Detailed information on CRRT technique is 
provided in Supplementary Table S3 (Supplemental Digital 
Content 1, http://links.lww.com/CCM/E888).
PICU Admission and Outcome
Sepsis, renal, and respiratory failure were the three major PICU 
admission diagnoses (Table 1). Raw PICU mortality was 11.2% 
(216/1,927 admissions). PICU mortality of patients requiring 
CRRT was 54.4% (37/68 patients), whereas 3-month mor-
tality was 63.3% (43/68 patients). Univariate analyses showed 
no significant differences between survivors and nonsurvivors 
regarding baseline and clinical characteristics. In both groups, 
around 65% of the patients received CRRT within 24 hours 
after PICU admission. A combination of oliguria, fluid over-
load, and/or electrolyte imbalances was the predominant in-
dication for CRRT (Supplementary Table S4, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E888). In the 
group with a primary renal reason for admission, fluid overload 
was the major indication for CRRT among the nonsurvivors 
(29.7%) versus 9.7% among the survivors (p = 0.02). In the sur-
vivor group, tumor lysis syndrome was the major primary renal 
reason for admission (survivors 16.1% vs nonsurvivors 2.7%; 
p = 0.08) (Supplementary Table S5, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/E888). Of note, among the 
patients with fluid overload greater than 10%, fluid overload 
was the indication for CRRT in 72.7% (24/33 patients).
Percentage fluid overload at the start of CRRT differed sig-
nificantly between survivors and nonsurvivors (3.5% vs 13.6%, 
respectively; p ≤ 0.001) (Table 1). The majority of patients who 
survived their PICU stay (48.4%) had a 0–3% increase of their 
bodyweight at PICU admission. In contrast, almost 50% of the 
nonsurvivors showed a 10–20% increase of their bodyweight at 
PICU admission. In addition, 
the latter group received signifi-
cantly more diuretics (p = 0.02) 
and vasoactive support (p < 
0.001) when compared with 
PICU survivors. Vasoactive-
Inotropic Score scores did not 
differ between both groups. SCr 
and eGFR at PICU admission 
were not different between both 
groups.
Risk Factors of PICU 
Mortality
Risk factors of PICU mortality 
by univariate analyses were 
fluid overload at admission 
(% increase body weight), use 
of diuretics before the start of 
CRRT, and the need of vaso-
active support at the start of 
CRRT (Table 1). After multi-
variable adjustment, the im-
portant risk factors for PICU 
mortality were fluid overload 
Figure 1. Included subjects from PICU admissions from January 2006 until July 2017. CRRT = continuous 
renal replacement therapy, HSCT = hematopoietic stem cell transplant.
Raymakers-Janssen et al
e896 www.ccmjournal.org November 2019 • Volume 47 • Number 11
TABLE 1. Pediatric Cancer and Hematopoietic Stem Cell Transplant Patient Characteristics 
Overall and by PICU Survival Status
Variable
All Patients  
(n = 68)
PICU Survivors  
(n = 31)
PICU Nonsurvivors 
(n = 37) p
General patient characteristics     
 Male gender, n (%) 43 (63.2) 20 (64.5) 23 (62.1) 0.84
 Age (yr), median (IQR) 8.9 (3.3–8.9) 7.8 (2.8–13.8) 9.1 (4.1–12.8) 0.90
 Weight (kg), median (IQR) 27.0 (14.7–49.7) 25.9 (14.0–50.0) 31.0 (14.9–53.5) 0.49
 Oncology diagnosis, n (%)     
  Leukemia/lymphoma 38 (55.9) 21 (67.7) 17 (45.9) 0.07
  Solid tumor 17 (25.0) 6 (19.4) 11 (29.7) 0.33
  Brain tumor 1 (1.5) 0 1 (2.7) 0.32
  Stem cell: nononcologic 12 (17.6) 4 (12.9) 8 (21.6) 0.35
 Hematopoietic stem cell transplant, n (%) 23 (33.8) 9 (29.0) 14 (37.8) 0.45
Characteristics of PICU admission     
 PICU admission diagnosis, n (%)     
  Sepsis 12 (17.6) 4 (12.9) 8 (21.6) 0.35
  Renal injury 27 (39.7) 12 (38.7) 15 (40.5) 0.88
  Cardiovascular failure 4 (5.9) 2 (6.5) 2 (5.4) 0.86
  Respiratory failure 14 (20.6) 8 (25.8) 6 (16.2) 0.35
  Neurologic deterioration 5 (7.4) 2 (6.5) 3 (8.1) 0.80
  Liver failure 4 (5.9) 2 (6.5) 2 (5.4)) 0.86
  Postoperative 2 (2.9) 1 (3.2) 1 (2.7) 0.90
 Pediatric Index of Mortality 2 (%), median (IQR) 5.4 (1.9–17.6) 4.3 (2.1–18.2) 6.4 (1.7–17.8) 0.24
 Fluid overload at CRRT initiation (% increase body 
weight), median (IQR) (n = 64)
9.5 (2.3–17.4) 3.5 (0.0–10.0) 13.6 (7.9–19.0) < 0.001a
 Fluid overload category (n = 64), n (%)     
  0% to ≤ 3% 19 (27.9) 15 (48.4) 4 (10.8) 0.001a
  3% to ≤ 10% 16 (23.5) 9 (29.0) 7 (18.9) 0.26
  10% to ≤ 20% 19 (27.9) 1 (3.2) 18 (48.6) < 0.001a
  > 20% 10 (14.7) 3 (9.7) 7 (18.9) 0.77
 Within 24 hr CRRT, n (%) 45 (66.2) 21 (67.7) 24 (64.9) 0.81
 Diuretics at CRRT initiation, n (%) 43 (63.2) 15 (48.4) 28 (75.7) 0.02a
 Antibiotics at CRRT initiation, n (%) 43 (63.2) 17 (54.8) 26 (70.3) 0.84
 Vasoactive support at CRRT initiation, n (%) 38 (55.1) 10 (32.3) 28 (75.7) < 0.001a
 Vasoactive-Inotropic Score, median (IQR) 40.0 (11.8–52.25) 40.0 (6–50) 42 (12.7–54.4) 0.456
 Inotrope use, n     
  Norepinephrine 28 7 21 0.006a
  Epinephrine 4 1 3 0.032a
  Dobutamine 7 0 7 0.810
  Dopamine 11 1 10 0.005a
  Milrinone 5 2 3 0.364
  Vasopressin 1 0 1 0.589
 Mechanical ventilation at CRRT initiation, n (%) 61 (88.4) 26 (83.9) 35 (94.6) 0.53
 PICU length of stay (d), median (IQR) 13.0 (5.3–25.8) 13.0 (6.0–42.0) 13.0 (5.00–21.5) 0.15
(Continued )
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(% increase body weight) (OR, 1.08; 95% CI, 1.01–1.17; 
p = 0.034) and the need of vasoactive support at the start of 
CRRT (OR, 6.53; 95% CI, 1.85–23.08; p = 0.004) (Table 2). 
When fluid overload was analyzed dichotomously (<10% or 
>10%), an OR of 6.16 (95% CI, 1.74–21.8; p = 0.005) was 
found.
There were significantly more HSCT patients in the group 
with greater than 10% fluid overload compared with the less 
than or equal to 10% fluid overload group (45.5% vs 22.9%, re-
spectively; p = 0.05) (Supplementary Table S6, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E888). In addi-
tion, patients in the greater than 10% fluid overload group re-
ceived significantly more antibiotics (p = 0.038) and vasoactive 
support (p = 0.006) at CRRT initiation when compared with 
the less than or equal to 10% fluid overload group.
Correction SCr for Fluid Balance
Correction of SCr for fluid balance revealed significantly 
higher creatinine values compared with uncorrected values 
in patients with greater than 10% fluid overload from 3 days 
before CRRT (Supplementary Table S7, Supplemental Dig-
ital Content 1, http://links.lww.com/CCM/E888). In addition, 
adjustment of SCr for fluid balances shifted patients between 
KDIGO AKI strata, especially in this latter group.
Clinical Characteristics of AKI in Patients
From a total of 61 patients, daily SCr, urine output, and 
weight during the 7 days before the start of CRRT were avail-
able (Fig. 2). Initially, small increments in SCr were observed 
followed by an exponential increase 3 days before initiation 
of CRRT. Urine output showed a similar, though inverse, 
trend; however, urine production did not fall below the crit-
ical limit of oliguria, that is, 0.5 mL/kg/hr. In contrast, body-
weight increased daily with an increased bodyweight of greater 
than 5% already 5 days before to start of CRRT in the PICU 
nonsurvivors.
Renal Function at 3 Months After PICU Discharge
Of 25 patients who survived greater than 3 months after PICU 
discharge, follow-up data on renal function were available in 23 
patients (Supplementary Fig. S1, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/E888). Renal function after 
CRRT treatment had fully recovered in 15 patients (65.2%). 
One patient had an eGFR greater than 90 mL/min/1.73 m2 but 
showed persistent proteinuria (stage 1 CKD). Seven patients 
(34.8%) had a persistent eGFR less than 90 mL/min/1.73 m2 
more than 3 months after CRRT treatment, thereby fulfilling 
the criteria of a “new-onset CKD.” Of these seven patients, four 
patients had stage 2 CKD (mild reduction), one patient stage 
Renal function characteristics     
 Acute kidney injury at start CRRT, n (%)     
  Stage 1 1 (1.5) 1 (3.2) 0 0.278
  Stage 2 9 (13.2) 3 (9.7) 6 (16.2) 0.436
  Stage 3 58 (85.3) 27 (86.1) 31 (83.3) 0.952
 Baseline SCr (µmmol/L), median (IQR) (n = 60) 31.5 (18–48) 31.0 (18.7–47.3) 33.5 (16.2–51) 0.943
 SCr at CRRT initiation (µmmol/L), median (IQR) 138.50 (73.5–217.5) 128 (78–249) 142 (69.5–209) 0.526
 Estimated glomerular filtration rate at CRRT 
initiation, median (IQR)
31.51 (21.5–45.8) 28.84 (19.05–45.6) 32.5 (22.7–47.9) 0.492
CRRT = continuous renal replacement therapy, IQR = interquartile ranges, SCr = serum creatinine.
Sample sizes are 31 for PICU survivors and 37 for PICU nonsurvivors unless otherwise indicated in the table.
aSignificant p value.
TABLE 1. (Continued). Pediatric Cancer and Hematopoietic Stem Cell Transplant Patient 
Characteristics Overall and by PICU Survival Status
Variable
All Patients  
(n = 68)
PICU Survivors  
(n = 31)
PICU Nonsurvivors 
(n = 37) p
TABLE 2. Multivariate Analysis of Risk Factors for PICU Mortality
Variable β (se) Wald Degrees of Freedom Odds Ratio (95%CI) p
Leukemia -0.777 (0.640) 1.474 1 0.460 (0.131-1.612) 0.255
Fluid overload 0.081 (0.038) 4.514 1 1.084 (1.006-1.168) 0.034a
Diuretic -0.239 (0.771) 0.096 1 0.788 (0.174-3.568) 0.757
PICU length of stay -0.030 (0.014) 4.571 1 0.971 (0.944-0.998) 0.033a
Vasoactive support 1.876 (0.644) 8.471 1 6.526 (1.845- 23.080) 0.004a
aSignificant p value.
Raymakers-Janssen et al
e898 www.ccmjournal.org November 2019 • Volume 47 • Number 11
3a (mild-moderate reduction), one stage 3b (moderate-severe 
reduction), and one stage 4 (severe reduction).
DISCUSSION
This nationwide, multicenter, retrospective study showed that 
PICU mortality of pediatric cancer and HSCT patients requir-
ing CRRT at the PICU is high (around 55%). We found that 
fluid overload and the need of vasoactive support at initiation 
of CRRT were independent risk factors for PICU mortality. In 
addition, almost 30% of the survivors had new-onset CKD 3 
months after PICU discharge.
AKI in the general pediatric intensive care patient popula-
tion is common, with a prevalence around 30% (15). Two large 
studies in a mixed PICU cohort (both studies included general 
pediatric, surgical, and oncologic patients) found a PICU mor-
tality of patients with AKI requiring CRRT of 33% and 26%, 
respectively (15, 21). In our cohort of critically ill pediatric 
cancer and/or HSCT patients requiring CRRT, a PICU mor-
tality rate of 54% was found, which is substantially higher. This 
high mortality rate is in line with data on outcome of CRRT in 
HSCT patients found by the prospective pediatric CRRT reg-
istry, where a similar (55%) or even higher (94%) PICU mor-
tality was found (22, 23). Data 
on critically ill pediatric cancer 
patients with AKI are scarce. 
AKI in critically ill adult cancer 
patients has been associated 
with a mortality rate exceeding 
50% when renal replacement 
therapy is required (8, 24). In 
addition to the poor outcomes, 
AKI decreases the chances of 
achieving a complete remis-
sion and adversely affects long-
term survival in these patients 
as cancer therapy reduction or 
discontinuation is often neces-
sary to avoid treatment-related 
morbidity (25–27).
We identified two impor-
tant early risk factors for PICU 
mortality: fluid overload and 
the use of vasopressor therapy. 
Our data on the association 
of fluid overload with PICU 
mortality are in line with pre-
vious studies suggesting that 
fluid overload may predict 
risk of mortality (28–30). The 
OR for mortality of overall 
fluid overload of 1.08 in our 
study implies an 8% increase 
in mortality for each 1% in-
crease in amount fluid over-
load at initiation of CRRT. 
When fluid overload was ana-
lyzed dichotomously, patients 
with fluid overload greater 
than 10% were 6.16 times 
more likely to die than those 
with less than or equal to 10% 
fluid overload. This OR was 
higher when compared with 
several single-center stud-
ies using the same strata, in 
which ORs were found vary-
ing from 1.78 to 3.02 (29, 31). 
Figure 2. Serum creatinine, urine production, and fluid overload (% increase body weight) to diagnose acute 
kidney injury (AKI) in pediatric oncology and hematopoietic stem cell transplant patients in days before initiation 
of continuous renal replacement therapy (= day 0) in PICU survivors (A) and PICU nonsurvivors (B). Serum 
creatinine values are adjusted for fluid balance. IQR = interquartile range.
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The heterogeneity of the cohorts may be an explanation for 
the observed differences. Here, we studied solely critically ill 
pediatric cancer and HSCT patients, whereas in other studies, 
all PICU patients were included. Two studies compared out-
come between two groups with fluid overload: less than 20% 
and greater than 20% (32, 33). They showed that critically ill 
children receiving CRRT who had developed greater than 20% 
fluid overload before start of CRRT had an adjusted mortality 
OR of 6.1 (32) and 8.5 (33), in line with increased risk of mor-
tality with increasing fluid overload.
It is possible that increased fluid overload merely repre-
sented patients who were more critically ill or more hemody-
namically unstable and required greater fluid administration. 
This is supported by higher vasopressor use in the greater than 
10% fluid overload group and the association of use of va-
sopressor support and PICU mortality in the present study 
and which was also found in a number of previous studies 
(15, 34–36). However, the present study was not able to dif-
ferentiate between fluids provided for resuscitation purposes 
and those necessary for the main pathology required treat-
ments that (subtle) kidney (dys)function was not able to cope 
with. Interestingly, severity of illness as measured by PIM 2 
score was not different between survivors and nonsurvivors at 
PICU admission. However, it has been shown that such prog-
nostic scores fail to accurately predict the outcome of HSCT 
patients (37, 38).
Taken together, our data suggest that a practice of goal-
directed fluid therapy in order to prevent fluid overload without 
compromising the hemodynamic status of these patients might 
be beneficial in this patient population. Whether early initia-
tion of CRRT, that is, at a lower fluid overload threshold, might 
improve outcomes remains a matter of debate. Recently, two 
randomized controlled trials comparing an early strategy with 
a delayed strategy for the initiation of CRRT reported con-
flicting results (39, 40). With the data currently available, it is 
not possible to determine a definitive fluid overload threshold 
for CRRT initiation.
The international KDIGO definition of AKI is based on SCr 
increase from baseline and/or urine output (17). Critically ill 
pediatric cancer patients often have decreased creatinine pro-
duction secondary to immobilization-related loss of muscular 
cell mass, low protein intake, cachexia, and inflammation (41). 
All of these factors affect SCr, independently of renal function, 
and thus limit the sensitivity of creatinine as an early marker 
of kidney injury in this particular patient group. In addition, 
an increase in total body water due to fluid overload might 
blunt a rise in SCr levels by dilution (18, 19). Indeed, adjust-
ing SCr for fluid balance revealed significantly higher creati-
nine values compared with uncorrected values in patients with 
greater than 10% fluid overload. However, in clinical practice, 
values of SCr are not adjusted for the amount of fluid over-
load, still implying that unadjusted AKI stage may be difficult 
to use as a trigger for initiation of CRRT in clinical settings. 
Tubular damage due to nephrotoxic drugs causes renal sodium 
loss and interferes with renal concentration capacity, thereby 
obscuring the development of oliguria as a sign of impeding 
renal function. Therefore, it may take these patients longer to 
meet the official KDIGO criteria and consequently to receive 
appropriate treatment. Our results show that small changes in 
SCr were already noticed in the days before initiation of CRRT. 
From our clinical experience, these limited changes in SCr 
may probably not trigger the clinicians that the risk of AKI is 
enhanced. Zappitelli et al (42) described that a small postop-
erative increase of only 25% in SCr predicted the development 
of AKI in children who underwent cardiac surgery. In addition, 
after 3- to-5 year follow-up, 40–50% of these patients with AKI 
showed signs of CKD. These findings are in line with our data 
and underscore the need for clear and timely identification of 
patients at high risk for AKI.
We found that renal function 3 months after CRRT treat-
ment had fully recovered in 70% of the patients who were dis-
charged from PICU. Hence, 30% of the patients showed CKD 
based on eGFR. It is already known that there are late renal 
effects in childhood cancer treatment (43–45). Whether a his-
tory of CRRT treatment is an additional, and perhaps prevent-
able, risk factor for development of CKD in this specific patient 
population has not been studied yet. Based on results of this 
present study, close monitoring of kidney function in these 
patients is warranted.
One of the strengths of the present study is the multicenter 
national approach. However, we also acknowledge several lim-
itations. An inherent limitation of this study is its retrospective 
nature, and the fact that we rely on data that were collected 
from patients’ medical records primarily captured for clinical 
care, and not for research. Furthermore, limited number of in-
cluded patients, although relatively large for a pediatric study, 
and the risk for confounders between groups that remain de-
spite our multivariate adjustment, might have influenced the 
results. A large international prospective study might over-
come these limitations. We have only included pediatric cancer 
and HSCT patients who received CRRT. A control group of 
pediatric cancer and HSCT patients with AKI “not” requir-
ing CRRT was not included. This would have been very in-
teresting, especially as such a comparison may have revealed 
specific risk factors for the need of CRRT. In addition, the 
study period spans 12 years, which increases the likelihood of 
changes in clinical practice affecting the outcomes of patients. 
Finally, although our study is multicenter, generalizability may 
be limited due to differences in PICU practice patterns as well 
as standard of care in other countries.
CONCLUSIONS
In this retrospective, multicenter national cohort study, we 
show that PICU mortality of pediatric cancer and HSCT 
patients that require CRRT is high. We demonstrated that fluid 
overload and need for vasopressor support at initiation of 
CRRT predict PICU mortality.
Our results highlight the urgent need for multicenter pro-
spective studies in pediatric cancer and HSCT patients. These 
studies may reveal risk factors for AKI and may guide recom-
mendations for effective therapeutic interventions at an early 
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phase. In addition, data from these studies may help guide both 
intensivists and oncologists in risk stratification of patients in 
the decision-making process of allocation of PICU resources. 
It may also identify patients who may benefit from closer 
monitoring and early interventions. Finally, these studies may 
advance our understanding of critical illness in the context of 
pediatric oncology to further refine and reflect on our daily 
clinical practice.
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